Supplementary Materials

Identification of tyrosinase inhibitors and their structureactivity relationships via evolutionary chemical binding similarity and structure-based methods

Prasannavenkatesh Durai¹, Young-Joon Ko^{1,2}, Jin-Chul Kim¹, Cheol-Ho Pan¹, and Keunwan Park^{1,*}

* Correspondence: keunwan@kist.re.kr; Tel.: +82 33 650 3663

¹ Natural Product Informatics Research Center, KIST Gangneung Institute of Natural Products, Gangneung, 25451, Republic of Korea; prasanna@kist.re.kr, yjko@kist.re.kr, jckim@kist.re.kr, panc@kist.re.kr, keunwan@kist.re.kr

² Department of Bioinformatics and Life Science, Soongsil University, Seoul, 06978, Republic of Korea



Figure S1. The two-dimensional structures of the molecules other than the top seven tyrosinase inhibitors tested in our study.



Figure S2. The precision-recall (PR) curves of the pharmacophore model M10 for its multiple validation sets.



Figure S3. The receiver operating characteristic (ROC) curves of the pharmacophore model M10 for its multiple validation sets



Figure S4. The new actives other than the two representative chemicals are mapped in the chosen pharmacophore model M10.



Figure S5. The tyrosinase sequences related to food products in the PDB ids 1BUG (Sweet potato), 2Y9X (Mushroom), 6ELS (Apple), and 6HQI (Tomato) were aligned with the sequence of human tyrosinase. The conserved residues in their active sites are highlighted in black. Sequence numbers of human tyrosinase are labeled at the right end of the sequence. Green color represents the identical residues that are not located in the active site, and cyan represents the residues that are not in the active site but conserved in many species. The three residues (Glu256, Asn260, and His263) indicated by orange dotted lines are from mushroom tyrosinase that shows interactions with inhibitors in molecular docking (Figure S6). These three residues correspond to Glu345, Asn364, and His367 in human tyrosinase that also exhibits interactions with the inhibitors in molecular docking (Figure 4).



Figure S6. Molecular docking performed for the two representative inhibitors in the mushroom tyrosinase crystal structure (PDB id: 2Y9X). The tyrosinase inhibitors and tyrosinase amino acids are shown as cyan and grey sticks, respectively. The pi-pi interactions and hydrogen bonds are shown as dotted lines. Only the interacting residues are shown for clarity by hiding the Cu ions, and other tyrosinase residues in the surface background of mushroom tyrosinase's active site.

Chemical	BindingDB				
ID	MonomerID				
Molecule	50218206				
Molecule1	50218205				
Molecule4	50218210				
Molecule6	85774				
Molecule7	50031467				
Molecule9	50242238				
Molecule10	50139366				
Molecule11	50139367				
Molecule12	50139368				
Molecule14	50139370				
Molecule15	60953				
Molecule24	50065387				
Molecule25	50351096				
Molecule26	50180259				
Molecule27	50180261				
Molecule28	50193668				
Molecule29	50193669				
Molecule30	50193670				
Molecule32	50108046				
Molecule33	50193673				
Molecule34	50193672				
Molecule35	50219502				
Molecule36	50269344				
Molecule37	50269342				

Table S1. The pharmacophore fit values for all the previous inactives of human tyrosinase given in the table were zero.

- Molecule38 50269341
- Molecule53 50067044
- Molecule54 50266759
- Molecule55 50067028
- Molecule56 50296394
- Molecule57 50264832
- Molecule58 50296395
- resveratrol 23926
- Molecule60 50174558
- Molecule61 50176525
- Molecule62 50096003
- Molecule68 50366429
- Molecule69 50287120
- Molecule70 50287121
- Molecule76 50287128
- Molecule77 60928
- Molecule78 50176696
- Molecule79 50370694
- Molecule80 50176698
- Molecule81 50176699
- Molecule82 50176700
- Molecule83 50176701
- Molecule84 50205806
- Molecule85 50205807
- Molecule86 50205814
- Molecule87 50205815

Table S1 continued...

Table S2. The PR AUC values of the 40 pharmacophore models are given.

Model	New actives, previous actives, new inactives, previous inactives and decoys	New actives, new inactives, previous inactives and decoys	New actives and decoys	New actives and previous inactives	Previous actives and previous inactives	New actives and previous actives	Training set— new actives and new inactives (1 moderately active SPB0333 is considered positive)	New actives, new inactives, previous inactives and decoys (1 moderately active SPB03333 is considered positive)
M1	0.39	0.13	0.15	0.56	0.72	0.26	0.95	0.10
M2	0.43	0.10	0.12	0.42	0.76	0.15	0.86	0.11
M3	0.33	0.60	0.65	0.97	0.58	0.55	0.97	0.65
M4	0.36	0.49	0.57	1	0.58	0.43	0.93	0.55
M5	0.43	0.39	0.43	0.86	0.75	0.37	0.95	0.44
M6	0.37	0.10	0.13	0.42	0.69	0.17	0.91	0.12
M7	0.32	0.68	0.78	0.97	0.57	0.79	0.95	0.80
M8	0.37	0.48	0.54	1	0.58	0.43	0.92	0.52
M9	0.25	0.07	0.08	0.30	0.56	0.25	0.88	0.07
M10	0.32	0.75 (.92 if one moderately active molecule SPB03333 is considered active)	0.93	1	0.64	0.88 (.9 if 1 moderately active SPB03333 is included)	0.95	0.92
M11	0.35	0.75	0.84	0.97	0.58	0.76	0.95	0.84
M12	0.43	0.52	0.66	0.69	0.72	0.59	0.88	0.64
M13	0.41	0.35	0.40	0.74	0.70	0.38	0.94	0.39
M14	0.35	0.11	0.13	0.42	0.72	0.19	0.86	0.12
M15	0.36	0.74	0.79	0.95	0.57	0.55	0.97	0.79
M16	0.40	0.14	0.16	0.53	0.72	0.26	0.95	0.15
M17	0.38	0.20	0.21	0.54	0.70	0.27	0.92	0.20
M18	0.45	0.12	0.14	0.51	0.80	0.15	0.87	0.14
M19	0.40	0.15	0.19	0.45	0.72	0.19	0.91	0.17
M20	0.42	0.20	0.22	0.53	0.70	0.26	0.92	0.20

M21	0.37	0.20	0.21	0.53	0.71	0.26	0.91	0.19
M22	0.48	0.49	0.59	0.80	0.81	0.61	0.87	0.64
M23	0.43	0.52	0.66	0.69	0.73	0.59	0.90	0.64
M24	0.27	0.46	0.54	1	0.55	0.44	0.80	0.48
M25	0.30	0.23	0.28	0.40	0.57	0.34	0.70	0.22
M26	0.22	0.05	0.06	0.38	0.75	0.15	0.70	0.06
M27	0.44	0.14	0.18	0.41	0.74	0.18	0.90	0.16
M28	0.32	0.76	0.85	1	0.58	0.86	0.93	0.85
M29	0.43	0.19	0.20	0.55	0.79	0.26	0.95	0.18
M30	0.39	0.10	0.12	0.40	0.77	0.15	0.91	0.12
M31	0.31	0.63	0.69	0.70	0.56	0.72	0.81	0.72
M32	0.28	0.45	0.52	0.97	0.58	0.50	0.91	0.50
M33	0.41	0.19	0.20	0.57	0.79	0.27	0.97	0.19
M34	0.40	0.02	0.03	0.12	0.62	0.11	0.56	0.03
M35	0.42	0.47	0.52	0.75	0.73	0.48	0.88	0.58
M36	0.36	0.08	0.09	0.41	0.66	0.14	0.98	0.09
M37	0.29	0.04	0.06	0.23	0.57	0.24	0.88	0.05
M38	0.36	0.72	0.89	0.97	0.58	0.79	0.94	0.88
M39	0.42	0.24	0.25	0.72	0.76	0.26	0.90	0.26
M40	0.39	0.39	0.43	0.86	0.71	0.44	0.96	0.44